ÐÓ°ÉÔ­´´

Ermium Therapeutics, based in Paris, shows strong potential in developing treatments for autoimmune diseases. Operating on a B2B model, the company collaborates with biotech and pharmaceutical firms. Their focus on novel solutions sets them apart in a market where current treatments often prove ineffective. Supported by Fountain Healthcare Partners, Ermium Therapeutics is well-positioned to capture market interest and achieve breakthroughs in challenging health conditions.